ArticleScientific reports2023

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.

Anja Charlotte Lundgren Mortensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.